Evolus vs Organogenesis
EOLS and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EOLS and ORGO compare
Evolus is the larger company, worth 4.2 times as much as Organogenesis ($442M against $104M).
Evolus grew revenue faster over the last twelve months (13.9% versus 6.5% for Organogenesis).
Evolus keeps more of each dollar of sales as profit, with a net margin of −10.8% compared with −18.4% at Organogenesis.
Organogenesis scores higher on the StockData Score (10 against 6 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EOLS | ORGO |
|---|---|---|
| Size and price | ||
| Market cap | $442M | $104M |
| Share price | $6.69 | $0.812 |
| Change, 1 year | −7.3% | −86.7% |
| Change, 5 years | 17.4% | −91.8% |
| Beta (5Y) | 1.93 | 0.57 |
| Employees | 334 | 854 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× | 0.2× (better) |
| P/B | – | 0.7× |
| P/FCF | – | 5.0× |
| FCF yield | −4.1% | 20.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | 6.5% |
| Revenue growth, 5Y average | 39.4% (better) | 10.8% |
| EPS growth, 5Y average | – | 0.00% |
| Profitability | ||
| Gross margin | 66.7% | – |
| Operating margin | −5.9% (better) | −7.8% |
| Net margin | −10.8% (better) | −18.4% |
| FCF margin | −5.8% | 4.6% (better) |
| Return on equity | – | −44.1% |
| Return on invested capital | −20.2% (better) | −21.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.2× | – |
| Current ratio | 1.70 | 3.52 (better) |
| Altman Z-score | −1.53 | 1.26 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.0% | 53.2% |
| Held by insiders | 4.1% | – |
| Insider net buying, 12 months | −$1.8M | −$988K (better) |
| Short interest, % of float | 9.5% | – |
Go deeper
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.